Brokers Issue Forecasts for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Iovance Biotherapeutics in a research report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.23) per share for the quarter. HC Wainwright has a "Buy" rating and a $32.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2025 earnings at ($0.13) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million.

A number of other research analysts also recently issued reports on the company. Chardan Capital lowered their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a report on Monday. Piper Sandler lowered their price objective on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating on the stock in a research report on Friday, February 28th. The Goldman Sachs Group cut their price objective on Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a research report on Monday. Truist Financial dropped their price objective on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research note on Monday. Finally, Robert W. Baird cut their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $20.25.

Remove Ads

Iovance Biotherapeutics Stock Down 0.9 %

Shares of IOVA traded down $0.04 during mid-day trading on Monday, hitting $3.72. 6,012,770 shares of the company's stock traded hands, compared to its average volume of 10,024,906. The firm has a market capitalization of $1.13 billion, a P/E ratio of -2.49 and a beta of 0.53. The business's 50-day moving average price is $5.92 and its 200-day moving average price is $8.39. Iovance Biotherapeutics has a 1 year low of $3.58 and a 1 year high of $17.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IOVA. AlphaQuest LLC boosted its position in Iovance Biotherapeutics by 63.6% during the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $36,000. GF Fund Management CO. LTD. bought a new position in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $47,000. One68 Global Capital LLC purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at approximately $74,000. Finally, Quarry LP acquired a new stake in Iovance Biotherapeutics in the fourth quarter valued at approximately $74,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.